Neurocrine biosciences presents data on improvements over time with long-term use of ingrezza® (valbenazine) capsules in older and elderly patients at the american association for geriatric psychiatry 2023 annual meeting

San diego , march 3, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced it will present data analyzing the long-term outcomes of treating tardive dyskinesia (td) with ingrezza® (valbenazine) capsules in older (≥55 years) and elderly (≥65 years) patients from two studies (kinect™ 3-extension and kinect™ 4). these data (poster #nr-36, improvements over time with long-term valbenazine in older and elderly patients with tardive dyskinesia) are being presented at the american association for geriatric psychiatry (aagp) 2023 annual meeting from march 3­­­–6 in new orleans.
NBIX Ratings Summary
NBIX Quant Ranking